Rethinking the Lifeline

Does the commercial support system — as it exists today — inevitably compromise CME's independence? That's the question the Accreditation Council for CME will explore over the next year as it conducts its first-ever big-picture review of the funding process. It will examine a range of options, from leaving the system intact, to setting up a centralized grants repository, to limiting — or even prohibiting — pharmaceutical industry funding of CME. Since drug companies funnel about $1 billion

Register to view the full article

Register for and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.